BiotechTube

CXA-201 and metronidazole + Meropenem

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Complicated Intra-abdominal Infection

Conditions

Complicated Intra-abdominal Infection

Trial Timeline

Dec 23, 2011 → Oct 15, 2013

NCT ID
NCT01445678

About CXA-201 and metronidazole + Meropenem

CXA-201 and metronidazole + Meropenem is a phase 3 stage product being developed by Merck for Complicated Intra-abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01445678. Target conditions include Complicated Intra-abdominal Infection.

What happened to similar drugs?

4 of 20 similar drugs in Complicated Intra-abdominal Infection were approved

Approved (4) Terminated (3) Active (15)
✅Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
✅Daptomycin + VancomycinMerckApproved
✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
✅Co-artemetherNovartisApproved
🔄HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
🔄Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
🔄Imipenem+Cilastatin/RelebactamMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01445678Phase 3Completed

Competing Products

20 competing products in Complicated Intra-abdominal Infection

See all competitors
ProductCompanyStageHype Score
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
36
HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
47
HRS -8427 + Imipenem and Cilastatin SodiumJiangsu Hengrui MedicinePhase 2
31
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
40
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
35
CXA-101 + CeftazidimeMerckPhase 2
35
Ceftolozane/Tazobactam + MeropenemMerckPhase 2
35
Imipenem+Cilastatin/RelebactamMerckPhase 3
40
Daptomycin + VancomycinMerckApproved
35
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
35
CXA-201 + LevofloxacinMerckPhase 3
40
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
35
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
40
KLU156 + CoartemNovartisPhase 3
40
LYS228 + Standard of care therapyNovartisPhase 2
27
Artemether-lumefantrine (COA566)NovartisPhase 2/3
38
INE963NovartisPhase 2
35
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
35
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
35